缓释辅料市场机会、成长动力、产业趋势分析及 2024 - 2032 年预测

2024 年全球缓释辅料市场规模达到 14 亿美元，预计 2025 年至 2034 年的复合年增长率为 8.3%。缓释辅料因其能够在较长时间内控製药物释放的能力，在製药业中变得越来越重要。随着对有效的长期治疗方案的需求不断增长，这些赋形剂在旨在治疗慢性病的药物开发中变得不可或缺，最终增强治疗效果。

随着医疗保健提供者专注于提高患者依从性、减少副作用和优化治疗方案，对缓释药物製剂的需求正在迅速增加。这些赋形剂提供了一个方便的解决方案，确保患者全天都能获得所需的治疗效果，而无需频繁服药。随着全球慢性病的增加，缓释製剂的采用预计会增加，使得缓释辅料市场成为製药业的关键部分。此外，药物输送系统和药物成分的不断进步有望提高缓释辅料的整体有效性和功能性。

市场分为几个产品类别，包括聚合物、明胶、矿物质、糖和其他赋形剂。 2024年，聚合物引领市场，创造最高收入。聚合物因其多功能性而受到特别重视，因为它们可以根据特定患者的需求创建药物释放曲线。聚合物具有基质和涂层等多种结构可能性，被製药公司广泛用于开发创新的药物输送系统。这些系统不仅提高了药物的有效性，而且有助于提高患者的依从性，这对于长期治疗的成功至关重要。

就给药途径而言，缓释辅料市场分为口服、静脉（IV）、透皮、肌肉注射（IM）和其他形式。 2024 年口服给药占据市场主导地位，并贡献了可观的收入。由于给药方便，且不需要专门的设备或培训，口服药物成为患者的首选。片剂和胶囊等口服剂型由于其舒适性和熟悉性而更加受欢迎。此外，口服途径提供了更大的药物吸收表面积，从而增强了缓释製剂的整体有效性。

预计到 2034 年，美国缓释辅料市场规模将达到 9.674 亿美元。约有60%的成年人患有至少一种慢性疾病，对缓释製剂的需求很大，以确保稳定的治疗效果，同时减少服药频率。此外，药物成分和药物传输技术的不断进步，提高了缓释辅料的有效性，进一步推动了市场的成长。

目录

第 1 章：方法论与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业衝击力
  • 成长动力
    • 慢性病盛行率不断上升
    • 控释製剂需求不断成长
    • 技术进步
    • 认知和接受度不断提高
  • 产业陷阱与挑战
    • 开发成本高
• 成长潜力分析
• 监管格局
• 技术格局
• 创新格局
• 差距分析
• 波特的分析
• PESTEL 分析

第四章：竞争格局

• 介绍
• 公司市占率分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 竞争仪錶板

第 5 章：市场估计与预测：按产品类型，2021 年至 2034 年

• 主要趋势
• 聚合物
• 明胶
• 矿物质
• 糖
• 其他产品类型

第 6 章：市场估计与预测：按管理路线，2021 年至 2034 年

• 主要趋势
• 口服
• 静脉注射 (IV)
• 透皮
• 肌肉注射 (IM)
• 其他给药途径

第 7 章：市场估计与预测：按技术，2021 年至 2034 年

• 主要趋势
• 定向投放
• 微囊化
• 植入物
• Wurster 技术
• 凝聚
• 其他技术

第 8 章：市场估计与预测：按应用，2021 年至 2034 年

• 主要趋势
• 药品
• 营养保健品

第 9 章：市场估计与预测：按地区，2021 年至 2034 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第十章：公司简介

• BASF
• Ashland Global
• Colorcon
• Croda International
• DFE Pharma
• Eastman
• Evonik Industries
• FMC Corporation
• Gattefosse
• International Flavors & Fragrances
• JRS Pharma
• Merck
• Roquette
• Seppic
• Shin-Etsu Chemical

The Global Sustained-Release Excipients Market reached USD 1.4 billion in 2024 and is projected to exhibit a CAGR of 8.3% from 2025 to 2034. This market growth is primarily driven by the increasing prevalence of chronic diseases, such as diabetes, hypertension, and cardiovascular conditions, which demand long-term, ongoing medication management. Sustained-release excipients are becoming increasingly critical in the pharmaceutical industry due to their ability to provide controlled drug release over extended periods. As the need for effective, long-term treatment options continues to rise, these excipients are becoming indispensable in the development of drugs aimed at managing chronic conditions, ultimately enhancing therapeutic outcomes.

The demand for sustained-release drug formulations is rapidly increasing as healthcare providers focus on improving patient compliance, reducing side effects, and optimizing treatment regimens. These excipients offer a convenient solution, ensuring that patients receive the desired therapeutic effects throughout the day, without the need for frequent dosing. With chronic diseases on the rise globally, the adoption of sustained-release formulations is expected to increase, making the sustained-release excipients market a key segment in the pharmaceutical industry. Moreover, ongoing advancements in drug delivery systems and pharmaceutical ingredients are expected to enhance the overall effectiveness and functionality of sustained-release excipients.

The market is divided into several product categories, including polymers, gelatin, minerals, sugars, and other excipients. In 2024, polymers led the market, generating the highest revenue. Polymers are especially valued for their versatility, as they allow for the creation of drug release profiles tailored to specific patient needs. With various structural possibilities, such as matrices and coatings, polymers are widely used by pharmaceutical companies to develop innovative drug delivery systems. These systems not only improve drug effectiveness but also contribute to better patient adherence, which is essential for long-term therapeutic success.

In terms of route of administration, the sustained-release excipients market is segmented into oral, intravenous (IV), transdermal, intramuscular (IM), and other forms. Oral administration dominated the market in 2024, with significant revenue contributions. The ease of administration, coupled with the lack of need for specialized equipment or training, makes oral medications a preferred choice for patients. The popularity of oral dosage forms such as tablets and capsules is further boosted by their comfort and familiarity. Additionally, the oral route provides a larger surface area for drug absorption, which enhances the overall effectiveness of sustained-release formulations.

The U.S. sustained-release excipients market is expected to reach USD 967.4 million by 2034. The country led the North American market in 2024, driven by a high prevalence of chronic diseases. With around 60% of adults affected by at least one chronic condition, the demand for sustained-release formulations is significant, ensuring stable therapeutic effects while reducing the frequency of dosing. Moreover, continuous advancements in pharmaceutical ingredients and drug delivery technologies are enhancing the effectiveness of sustained-release excipients, further fueling the market's growth.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of chronic diseases
    • 3.2.1.2 Rising demand for controlled-release formulations
    • 3.2.1.3 Technological advancements
    • 3.2.1.4 Growing awareness and acceptance
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High development cost
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
• 3.6 Innovation landscape
• 3.7 Gap analysis
• 3.8 Porter’s analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Competitive dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Polymers
• 5.3 Gelatin
• 5.4 Minerals
• 5.5 Sugars
• 5.6 Other product types

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Oral
• 6.3 Intravenous (IV)
• 6.4 Transdermal
• 6.5 Intramuscular (IM)
• 6.6 Other routes of administration

Chapter 7 Market Estimates and Forecast, By Technology, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Targeted delivery
• 7.3 Microencapsulation
• 7.4 Implants
• 7.5 Wurster technique
• 7.6 Coacervation
• 7.7 Other technologies

Chapter 8 Market Estimates and Forecast, By Application, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Pharmaceuticals
• 8.3 Nutraceuticals

Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 BASF
• 10.2 Ashland Global
• 10.3 Colorcon
• 10.4 Croda International
• 10.5 DFE Pharma
• 10.6 Eastman
• 10.7 Evonik Industries
• 10.8 FMC Corporation
• 10.9 Gattefosse
• 10.10 International Flavors & Fragrances
• 10.11 JRS Pharma
• 10.12 Merck
• 10.13 Roquette
• 10.14 Seppic
• 10.15 Shin-Etsu Chemical